What Is Klotho Genotype

The Klotho KL-VS variant is a specific haplotype in the human KL gene, defined by two linked amino acid changes (F352V and C370S) in the alpha-Klotho protein. Carrying one copy of this variant is associated with higher circulating levels of soluble Klotho, a hormone-like factor involved in mineral metabolism, kidney function, and cellular stress resistance. Approximately one in five people of European ancestry is heterozygous for KL-VS, and this single-copy carrier status has been linked in population studies to enhanced cognition and modestly longer lifespan.

Klotho was originally identified in mice, where loss of the gene causes a syndrome resembling accelerated aging: shortened lifespan, vascular calcification, skin atrophy, and organ deterioration. In humans, circulating soluble Klotho declines with age, and lower levels track with kidney disease progression, cardiovascular calcification, cognitive decline, and increased mortality. The KL-VS variant matters because it is one of the few common genetic polymorphisms with a reproducible association with human longevity and cognitive resilience.

From a longevity perspective, understanding KL-VS carrier status offers a window into an individual's baseline Klotho biology. Because Klotho acts as an endocrine factor that modulates phosphate handling, insulin and IGF-1 signaling, Wnt pathway activity, and oxidative stress defenses, its influence ripples across multiple aging hallmarks. Knowing whether someone carries zero, one, or two copies of KL-VS can inform how aggressively they might pursue strategies to support Klotho-related pathways through exercise, kidney protection, and metabolic optimization.

The KL gene on chromosome 13 encodes a single-pass transmembrane protein expressed primarily in the kidney and brain. The extracellular domain can be cleaved by secretases and released into the blood, cerebrospinal fluid, and urine as soluble alpha-Klotho. This soluble form acts at a distance, functioning as a co-receptor for fibroblast growth factor 23 (FGF23) to regulate phosphate and vitamin D metabolism, and independently suppressing insulin/IGF-1 signaling, inhibiting Wnt pathway overactivation, and enhancing cellular antioxidant defenses.

The KL-VS haplotype introduces two amino acid substitutions in exon 2 of the KL gene. The F352V change, in particular, appears to increase the secretion of soluble Klotho from expressing cells, raising circulating levels by a measurable margin in heterozygous carriers. This elevation is consistent across multiple ethnic groups studied. The result is a lifelong, modest upward shift in a circulating factor that counterbalances several pro-aging signals.

The heterozygote advantage pattern is central to understanding KL-VS. One copy raises soluble Klotho and correlates with better executive function, larger prefrontal cortex volume in older adults, slower kidney function decline, and reduced cardiovascular calcification. Two copies, however, appear to reduce Klotho secretion below even the levels seen in non-carriers, possibly because the double amino acid substitution interferes with protein processing or stability. This dosage sensitivity means that genotype interpretation requires distinguishing heterozygotes from homozygotes, not simply asking whether someone carries the variant.

The association between heterozygous KL-VS carrier status and increased lifespan has been replicated in several independent cohorts, including populations of European and African American ancestry. A well-cited study of three independent community-based cohorts found that KL-VS heterozygotes lived longer and performed better on cognitive testing than non-carriers or homozygotes. Neuroimaging studies have demonstrated that KL-VS heterozygotes maintain greater prefrontal cortex gray matter volume in later life. Animal experiments with Klotho overexpression consistently show lifespan extension, improved cognition, and resistance to neurodegenerative pathology, providing biological plausibility for the human genetic findings.

Important gaps remain. The precise molecular mechanism by which the F352V substitution increases soluble Klotho secretion is not fully characterized. Whether the cognitive and longevity associations hold equally across all ethnic groups needs broader study, as most large cohorts have been of European descent. No clinical trials have yet tested whether exogenous Klotho administration or pharmacological Klotho enhancement can recapitulate the benefits seen in carriers. The paradox of homozygous disadvantage also lacks a complete mechanistic explanation. Research into Klotho-boosting interventions (exercise protocols, FGF23 modulators, recombinant Klotho fragments) is active but largely preclinical.

KL-VS genotyping itself carries no physical risk, but interpreting results requires nuance. The longevity and cognitive associations are population-level averages with modest effect sizes; individual outcomes depend on a vast network of other genetic and environmental factors. Homozygous carriers should not assume poor health outcomes, just as heterozygous carriers should not assume protection from cognitive decline or kidney disease. Direct-to-consumer genetic tests vary in their coverage of the relevant SNPs, and raw data interpretation without professional guidance can lead to misunderstanding. Soluble Klotho blood testing, while increasingly available, lacks standardized reference ranges and clinical guidelines for action.